Trial · NCT02869438
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1 | From first IP dose to Day 84 | Full analysis set | Liter | MEAN |
| PRIMARY | Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV) | From first IP dose to Day 84 | Body plethysmography sub-study analysis set | Liter | MEAN |
| SECONDARY | Percent Change From Baseline to End of Treatment in Eosinophils Counts | From first IP dose to Day 84 | Full analysis set | Percent change | MEAN |
| SECONDARY | Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1 | From first IP dose to Day 84 | Full analysis set | Liter | MEAN |
| SECONDARY | Change From Baseline to Post Baseline for Pre-BD FVC | From first IP dose to Day 84 | Full analysis set | Liter | MEAN |
| SECONDARY | Percentage of Pre-BD FEV1 Responder | From first IP dose to Day 84 | Full analysis set | Percentage of Participants | NUMBER |
| SECONDARY | Change From Baseline in ACQ-6 | From first IP dose to Day 84 | Full analysis set | Score on a scale | MEAN |
| SECONDARY | Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) | From first IP dose to Day 84 | Full analysis set | Score on a scale | MEAN |
| SECONDARY | Change From Baseline to End of Treatment in FeNO | From first IP dose to Day 84 | Full analysis set | ppb | MEAN |
| SECONDARY | Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients | From first IP dose to Day 84 | Body plethysmography sub-study analysis set | Liter | MEAN |
| SECONDARY | Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients | From first IP dose to Day 84 | Body plethysmography sub-study analysis set | ratio | MEAN |
| SECONDARY | Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients | From first IP dose to Day 84 | Body plethysmography sub-study analysis set | Liter | MEAN |
| SECONDARY | Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients | From first IP dose to Day 84 | Body plethysmography sub-study analysis set | Liter | MEAN |
| SECONDARY | Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients | From first IP dose to Day 84 | Body plethysmography sub-study analysis set | Liter | MEAN |
| SECONDARY | Duration of IP Administration | From first IP to last IP | Safety analysis set | Days | MEAN |
| OTHER_PRE_SPECIFIED | Serum Concentration of Benralizumab | From first dose to end of treatment period (Day 84) | PK analysis set | ng/mL | GEOMETRIC_MEAN |
| OTHER_PRE_SPECIFIED | PK Parameter of Benralizumab (Cmax) | First IP dose cycle (ie, data collected on Days 3, 7, 14 and 28) | PK analysis set | ng/mL | GEOMETRIC_MEAN |
| OTHER_PRE_SPECIFIED | Anti-drug Antibody Responses | From first IP dose to end of treatment period (Day 84) | Safety analysis set | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Change From Baseline to End of Treatment in PGI-S | From first IP dose to Day 84 | Full analysis set | Score on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline to End of Treatment in CGI-C | From first IP dose to Day 84 | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02869438/outcomes